Sign In
Buy CEVI
CellaVision AB (publ) Earnings Calls
| Release date | Nov 06, 2025 |
| EPS estimate | kr1.36 |
| EPS actual | kr1.31 |
| EPS Surprise | -3.68% |
| Revenue estimate | 180M |
| Revenue actual | 175.617M |
| Revenue Surprise | -2.44% |
| Release date | Jul 18, 2025 |
| EPS estimate | kr1.52 |
| EPS actual | kr1.58 |
| EPS Surprise | 3.95% |
| Revenue estimate | 187M |
| Revenue actual | 191.328M |
| Revenue Surprise | 2.31% |
| Release date | May 02, 2025 |
| EPS estimate | kr1.38 |
| EPS actual | kr1.74 |
| EPS Surprise | 26.09% |
| Revenue estimate | 179.125M |
| Revenue actual | 194.802M |
| Revenue Surprise | 8.75% |
| Release date | Feb 06, 2025 |
| EPS estimate | kr1.93 |
| EPS actual | kr1.72 |
| EPS Surprise | -10.88% |
| Revenue estimate | 202.525M |
| Revenue actual | 186.688M |
| Revenue Surprise | -7.82% |
Last 4 Quarters for CellaVision AB (publ)
Below you can see how CEVI.ST performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 06, 2025 |
| Price on release | kr205.00 |
| EPS estimate | kr1.93 |
| EPS actual | kr1.72 |
| EPS surprise | -10.88% |
| Date | Price |
|---|---|
| Jan 31, 2025 | kr226.50 |
| Feb 03, 2025 | kr216.50 |
| Feb 04, 2025 | kr221.50 |
| Feb 05, 2025 | kr222.50 |
| Feb 06, 2025 | kr205.00 |
| Feb 07, 2025 | kr201.00 |
| Feb 10, 2025 | kr201.50 |
| Feb 11, 2025 | kr197.00 |
| Feb 12, 2025 | kr194.00 |
| 4 days before | -9.49% |
| 4 days after | -5.37% |
| On release day | -1.95% |
| Change in period | -14.35% |
| Release date | May 02, 2025 |
| Price on release | kr207.50 |
| EPS estimate | kr1.38 |
| EPS actual | kr1.74 |
| EPS surprise | 26.09% |
| Date | Price |
|---|---|
| Apr 25, 2025 | kr162.40 |
| Apr 28, 2025 | kr161.00 |
| Apr 29, 2025 | kr197.60 |
| Apr 30, 2025 | kr202.00 |
| May 02, 2025 | kr207.50 |
| May 05, 2025 | kr200.00 |
| May 06, 2025 | kr199.00 |
| May 07, 2025 | kr194.60 |
| May 08, 2025 | kr195.60 |
| 4 days before | 27.77% |
| 4 days after | -5.73% |
| On release day | -3.61% |
| Change in period | 20.44% |
| Release date | Jul 18, 2025 |
| Price on release | kr183.20 |
| EPS estimate | kr1.52 |
| EPS actual | kr1.58 |
| EPS surprise | 3.95% |
| Date | Price |
|---|---|
| Jul 14, 2025 | kr179.20 |
| Jul 15, 2025 | kr180.60 |
| Jul 16, 2025 | kr179.40 |
| Jul 17, 2025 | kr180.60 |
| Jul 18, 2025 | kr183.20 |
| Jul 21, 2025 | kr174.20 |
| Jul 22, 2025 | kr172.60 |
| Jul 23, 2025 | kr177.80 |
| Jul 24, 2025 | kr178.60 |
| 4 days before | 2.23% |
| 4 days after | -2.51% |
| On release day | -4.91% |
| Change in period | -0.335% |
| Release date | Nov 06, 2025 |
| Price on release | kr160.00 |
| EPS estimate | kr1.36 |
| EPS actual | kr1.31 |
| EPS surprise | -3.68% |
| Date | Price |
|---|---|
| Oct 31, 2025 | kr180.00 |
| Nov 03, 2025 | kr181.80 |
| Nov 04, 2025 | kr177.40 |
| Nov 05, 2025 | kr176.00 |
| Nov 06, 2025 | kr160.00 |
| Nov 07, 2025 | kr165.20 |
| Nov 10, 2025 | kr160.00 |
| Nov 11, 2025 | kr160.60 |
| Nov 12, 2025 | kr159.20 |
| 4 days before | -11.11% |
| 4 days after | -0.500% |
| On release day | 3.25% |
| Change in period | -11.56% |
CellaVision AB (publ) Earnings Call Transcript Summary of Q3 2025
Q3 2025 was a mixed but fundamentally healthy quarter for CellaVision. Reported net sales were SEK 176m, down 1.7% year-over-year but up 2.6% organically once a -4.3% FX headwind is removed. Gross margin improved to 69% (up 1ppt) driven by price increases and favorable product mix (more large systems). EBITDA rose slightly to SEK 50m (28% margin). Operating investments fell modestly YoY, R&D spend remains a strategic priority (24% of sales) though capitalized R&D was lower this quarter (SEK 14m) due to seasonality and completion of a software upgrade. Cash flow from operations was SEK ~30m, after working capital effects cash flow was SEK 4m. Regionally: Americas +4% organic (good traction on large platforms, Latin America pickup); EMEA ~1% organic (strong reagent growth, modest hematology demand); APAC soft and lumpy (SEK 13m) influenced by manufacturing/shipments to China but reagents showing early momentum. Strategic highlights: clinical trial completed and CE submission for the bone marrow application with expectation of CE marking in early 2026 (Q1); a major software upgrade has been verified and is being installed at customer sites for final validation and will roll out imminently (November) — it will be provided as part of the instrument package (no extra fee). The company continues to invest in next-generation FPM microscopy and expansion beyond hematology, and is executing a 'Made in China' manufacturing initiative with partner Sysmex to enable participation in local tenders. Management remains cautiously optimistic on demand trends (especially larger systems) but acknowledges regional lumpiness and competitive dynamics in China.
